Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

ClinicalTrials.gov ID: NCT05616013

Public ClinicalTrials.gov record NCT05616013. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women

Study identification

NCT ID
NCT05616013
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
507 participants

Conditions and interventions

Interventions

Biological · Drug · Other

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 16, 2022 (Actual)
Primary completion
May 16, 2024 (Actual)
Completion
Jun 14, 2025 (Actual)
Last update posted
Jul 8, 2026

2022 – 2025

United States locations

U.S. sites
10
U.S. states
7
U.S. cities
10
Facility City State ZIP Site status
Pinnacle Research Group, LLC Anniston Alabama 36207 —
Cullman Clinical Trials Cullman Alabama 35055 —
Indago Research & Health Center, Inc Hialeah Florida 33012 —
Clinical Neuroscience Solutions Inc Jacksonville Florida 32256 —
Altus Research Lake Worth Florida 33461 —
Pennington Biomedical Research Center Baton Rouge Louisiana 70808 —
Weill Cornell Medical College New York New York 10021 —
Monroe Biomedical Research Monroe North Carolina 28112 —
SPICA Clinical Columbia South Carolina 29322 —
Mt. Olympus Medical Research Sugar Land Texas 77479 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05616013, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 8, 2026 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05616013 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →